ライフサイエンスコーパス: chromogranin

1 he fragment reversed the enhancing effect of chromogranin.

2 o-aggregation of other proteins, such as the chromogranins.

3 in, performance status, tumor burden, plasma chromogranin A (>/=600 mug/L), neuron-specific enolase (

4 PA PET/CT results had higher values of serum chromogranin A (100% vs. 20%, P = 0.0003), serotonin, or

5 strin (1031 pg/ml; reference value <108) and chromogranin A (337 U/L; reference value <36).

6 ol as a well-known marker of stress loading, chromogranin A (CgA) and alpha-amylase (AA) are supposed

7 Results showed that proteolytic fragments of chromogranin A (CgA) and chromogranin B (CgB) represent

8 secretory vesicles of neuroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been

9 LDCV formation involves the granin proteins chromogranin A (CgA) and chromogranin B (CgB); CgA- and

10 Chromogranin A (CgA) and neuron-specific enolase (NSE) w

11 Immunohistochemical (IHC) measurement of chromogranin A (CgA) discriminates gastrointestinal (GI)

12 Previously, chromogranin A (CgA) has been shown to play a key role i

13 afficking of the regulated secretory protein chromogranin A (CgA) in PC12 cells.

14 Chromogranin A (CgA) is the major soluble protein in the

15 Chromogranin A (CgA) levels have previously been found t

16 Chromogranin A (CgA) may be critical for secretory granu

17 n active 21-residue peptide derived from the chromogranin A (CgA) precursor, and catestatin is secret

18 ing and organ colonization were inhibited by chromogranin A (CgA), a protein present in variable amou

19 ctors to 125 species and observed that fecal chromogranin A (CgA), a protein secreted by enteroendocr

20 found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroend

21 stores in which the Ca(2+) storage protein, chromogranin A (CGA), couples with InsP(3)-gated Ca(2+)

22 gnosis is established by elevation of plasma chromogranin A (CgA), serotonin, or urinary 5-hydroxyind

23 r Musashi-1 (Msi-1), neurogenin 3 (NEUROG3), chromogranin A (CgA), serotonin, peptide YY (PYY), oxynt

24 Chromogranin A (CgA), the major soluble protein in catec

25 Chromogranin A (CgA), which binds catecholamines for sto

26 e neuroendocrine (NE) markers calcitonin and chromogranin A (CgA).

27 cription of the major vesicular core protein chromogranin A (CgA).

28 secretion in endocrine cells is dependent on chromogranin A (CGA).

29 n, increased tumor grade, and elevated serum chromogranin A (CgA).

30 cells, we show that SgIII is complexed with Chromogranin A (CgA).

31 the N- and C-terminal regions of circulating chromogranin A (CgA, CHGA), classically an antiangiogeni

32 Chromogranin A (CHGA) and its derived peptides, which ar

33 es, we have identified the peptide WE14 from chromogranin A (ChgA) as the antigen for highly diabetog

34 Chromogranin A (ChgA) has been identified as the antigen

35 Recent studies suggest an important role of chromogranin A (CHGA) in the regulated secretory pathway

36 Chromogranin A (ChgA) is an autoantigen for CD4(+) T cel

37 The acidic glycoprotein chromogranin A (CHGA) is co-stored/co-secreted with cate

38 Chromogranin A (CHGA) is coreleased with catecholamines

39 The secretory pro-hormone chromogranin A (CHGA) is densely packed into storage gra

40 The secretory prohormone chromogranin A (CHGA) is overexpressed in essential hype

41 etermine whether the common variation at the chromogranin A (CHGA) locus increases susceptibility to

42 Whether chromogranin A (CHGA) polymorphisms predict end-organ co

43 Chromogranin A (CHGA) regulates catecholamine storage an

44 Chromogranin A (CHGA) regulates the storage and release

45 Chromogranin A (CHGA) triggers catecholamine secretory g

46 Chromogranin A (CHGA), a protein released from secretory

47 mine release inhibitory peptide derived from chromogranin A (CHGA), and other CHGA- or chromogranin B

48 ied the beta cell secretory granule protein, chromogranin A (ChgA), as a new autoantigen in type 1 di

49 tide derived from the neuroendocrine protein chromogranin A (CHGA), is a functional AMP and is presen

50 Chromogranin A (Chga), which catalyzes formation and car

51 Catestatin (CST), a chromogranin A (CHGA)-derived peptide, is a potent inhib

52 Chromogranin A (CHGA/Chga), a proprotein, widely distrib

53 esicular monoamine transporter (VMAT1,2) and chromogranin A (ChrgA), are also expressed in taste buds

54 ng for mucosal 5-HT synthesis; P < 0.01] and chromogranin A (neuroendocrine secretion; P < 0.01), wit

55 and neuroendocrine markers synaptophysin and chromogranin A (P < 0.0000001).

56 s of the CT pulmonary angiographic findings, chromogranin A and 5-hydroxyindoleacetic acid levels wer

57 Tumor markers (chromogranin A and 5-hydroxyindoleacetic acid) before an

58 levels of oxytocin and peptides derived from chromogranin A and B dramatically decreased in the PC1 K

59 proopiomelanocortin, protachykinins A and B, chromogranin A and B, and secretogranin II.

60 ically abolished regulated secretion of both chromogranin A and beta-endorphin in response to the usu

61 GFI1 colocalizes with chromogranin A and calcitonin-gene-related peptide in em

62 nclude insulin and the two new autoantigens, chromogranin A and islet amyloid polypeptide, all protei

63 Thus, chromogranin A and its catestatin fragment may lie at th

64 a radioimmunoassays showed elevated gastrin, chromogranin A and normal levels of gastrin-releasing pe

65 Staining is negative for chromogranin A and positive for bombesin, serotonin, neu

66 alize with secretory granule markers such as chromogranin A and Rab27b, whereas Myo5c tubules are lab

67 r panendocrine immunohistochemistry markers (chromogranin A and/or synaptophysin); 35% of NETs demons

68 Chromogranin A appears to be the most useful serum marke

69 In summary, common variants in chromogranin A associate with the risk of hypertensive E

70 efore probed the role of the MAPK pathway in chromogranin A biosynthesis after secretory stimulation

71 We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment

72 t, removing the C-terminal 90 amino acids of chromogranin A caused rerouting to the constitutive secr

73 ells revealed reciprocal changes in secreted chromogranin A COOH-terminal fragments (increased approx

74 Point mutations of the chromogranin A CRE suggested that this element was neces

75 Both the MAPK pathway and chromogranin A expression may be activated by cytosolic

76 Serum markers include chromogranin A for neuroendocrine tumors, pepsinogen I f

77 tely 71 and approximately 27 kD NH2-terminal chromogranin A fragments.

78 PACAP activated the endogenous chromogranin A gene by four- to fivefold.

79 IGF-I stimulated chromogranin A gene expression by Northern blot analysis

80 led with assay of histidine decarboxylase or chromogranin A gene expression is useful in the assessme

81 ed whether PACAP regulates expression of the chromogranin A gene in PC12 rat chromaffin cells, so as

82 Chromogranin A immunoblots revealed chromogranin A proce

83 tion was used to analyze the distribution of chromogranin A immunoreactive cells in serial sections o

84 injection, total insulin content and insulin:chromogranin A immunoreactivity were reduced by approxim

85 hemistry demonstrated a relative decrease of chromogranin A in processes (where regulated secretory v

86 retory granules, and stimulated secretion of chromogranin A increased 50%.

87 Specific endopeptidases cleave chromogranin A into biologically active peptide fragment

88 These results demonstrate that chromogranin A is a substrate for the endogenous endopro

89 The catestatin fragment of chromogranin A is an endogenous inhibitor of nicotinic c

90 The catestatin fragment of chromogranin A is an inhibitor of catecholamine release,

91 This region of chromogranin A is extensively processed within chromaffi

92 Chromogranin A is released together with epinephrine and

93 Since chromogranin A is secreted along with catecholamines, we

94 Chromogranin A is the major soluble core component in se

95 Chromogranin A knock-out (Chga-KO) mice display increase

96 Chromogranin A knockout (Chga-KO) mice exhibit enhanced

97 ng a greater than 50% reduction in the nadir chromogranin A level within the 1st year after treatment

98 estimated absorbed BM dose, elevated plasma chromogranin A level, baseline blood counts, and renal f

99 Chromogranin A levels were significantly higher in both

100 rmal, as were 5-hydroxyindoleacetic acid and chromogranin A levels.

101 on of PCl suggests that the action of PC1 on chromogranin A may be specific within the chromogranin/s

102 and calcitonin and suggest that the role of chromogranin A may be to stabilize an otherwise unstable

103 This small domain within chromogranin A may contribute to a novel, autocrine, hom

104 owledge of cleavage sites of catestatin from chromogranin A may provide a useful starting point in an

105 function, e.g., histidine decarboxylase and chromogranin A messenger RNA abundance, in carcinoid tum

106 NH2-terminal fragment as well as the parent chromogranin A molecule accumulated, while an approximat

107 eprazole, VMAT2, histidine decarboxylase and chromogranin A mRNA abundance in gastric corpus, and pla

108 Chromogranin A mRNA responded to MAPK pathway manipulati

109 Chromogranin A mRNA showed a time-dependent 3.87-fold re

110 n L-DsRed fusion protein with enkephalin and chromogranin A neuropeptides that are present in secreto

111 isense PC1 induction, an approximately 66-kD chromogranin A NH2-terminal fragment as well as the pare

112 otyping, including catecholamine production, chromogranin A precursor, and its catestatin product.

113 Chromogranin A immunoblots revealed chromogranin A processing, from both the NH2 and COOH te

114 A series of chromogranin A promoter 5' deletion mutant/luciferase re

115 markedly diminished trans-activation of the chromogranin A promoter by PACAP.

116 r was in linkage disequilibrium with 1 major Chromogranin A promoter haplotype, although promoter hap

117 cis, activation by the cascade maps onto the chromogranin A promoter proximal CRE, which is both nece

118 , and calcium-dependent signals map onto the chromogranin A promoter proximal CRE.

119 oximal CRE box is entirely necessary for the chromogranin A promoter response to PACAP.

120 kinase blocked the response of a transfected chromogranin A promoter to nicotine or protein kinase C

121 antagonist KCREB blocked the response of the chromogranin A promoter to nicotine, cAMP, or MAPK pathw

122 protein kinase C mapped principally onto the chromogranin A promoter's cAMP response element (TGACGTA

123 ltimately relays the secretory signal to the chromogranin A promoter's CRE box in cis.

124 tion in a fashion similar to the transfected chromogranin A promoter, in both direction and magnitude

125 n enhanced basal as well as IGF-I-stimulated chromogranin A promoter.

126 fection of pathway components stimulated the chromogranin A promoter.

127 we employed a novel mouse strain harboring a chromogranin A promoter/firefly luciferase reporter tran

128 e obtained with a transfected 1,200-bp mouse chromogranin A promoter/luciferase reporter construct.

129 Transfected chromogranin A promoter/luciferase reporter constructs w

130 edistribution of desmoplakin, keratin 5, and chromogranin A proteins.

131 his peptide blocked the inhibitory effect of chromogranin A proteolytic fragments on nicotinic-stimul

132 atecholamine release, and was shared by this chromogranin A region from several species.

133 ced secretion, transcriptional activation of chromogranin A remained unaltered.

134 sphatase and the regulated secretory protein chromogranin A resulted in an increased chromogranin sto

135 Plasma cortisol and chromogranin A showed a significant association that did

136 ization domain did not affect the sorting of chromogranin A to the regulated secretory pathway.

137 Thus, PACAP-evoked chromogranin A transcription and catecholamine secretion

138 -binding protein CREB, blunted activation of chromogranin A transcription by nicotine, phorbol ester,

139 We conclude that activation of chromogranin A transcription by secretory stimulation in

140 receptor antagonist PACAP6-38 impaired both chromogranin A transcription or catecholamine secretion

141 Therefore, we propose that PACAP signals to chromogranin A transcription through the CRE in cis, and

142 bited both forskolin and PACAP activation of chromogranin A transcription, revealing that PACAP-induc

143 timuli influence exocytotic secretion versus chromogranin A transcription.

144 Chromogranin A was identified as a promising marker for

145 a new phosphorylation site (S191) in bovine chromogranin A was identified.

146 eporter and the neuroendocrine-specific gene chromogranin A was induced 2-3.3-fold by insulin-like gr

147 Synthetic longer (chromogranin A(332-364)) and shorter (chromogranin A(344

148 trometry, a major catestatin form was bovine chromogranin A(332-364); identity of the peptide was con

149 alysis revealed two additional forms: bovine chromogranin A(333-364) and A(343-362).

150 omaffin granules, with the major form, human chromogranin A(340-372), bounded by dibasic sites.

151 onger (chromogranin A(332-364)) and shorter (chromogranin A(344-364)) versions of catestatin each inh

152 ratin 20), acinar (chymotrypsin), and islet (chromogranin A) cell markers was performed to analyze th

153 as associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic r

154 marker MTA1, the apoptotic marker NALP, and chromogranin A) that define gut neuroendocrine cell beha

155 biosynthesis of the major secreted protein (chromogranin A), that the activation is transcriptional,

156 Among 37 patients with elevated chromogranin A, 26 (70%) achieved normalization or more

157 Serum chromogranin A, a marker for neuroendocrine tumors, is e

158 nase) blocked nicotinic or PMA activation of chromogranin A, although a dominant negative Ras mutant

159 ch activation, and secretory markers Mucin2, Chromogranin A, and Growth factor-independent 1 (Gfi1) w

160 Different amidation events on chromogranin A, and on peptides processed from proopiome

161 rade [poorly differentiated], respectively), chromogranin A, and proliferation index (Ki-67).

162 found extensive processing of catestatin in chromogranin A, as judged by catestatin radioimmunoassay

163 in positively for alpha-tubulin, mucins, and chromogranin A, as well as for endoderm transcription fa

164 ntestinal enteroendocrine cells positive for chromogranin A, but they had normal numbers of Paneth's,

165 Chromogranin A, chromogranin B, and secretogranin II, me

166 ocortin (POMC), provasopressin, prooxytocin, chromogranin A, chromogranin B, and secretogranin II.

167 Chromogranin A, coreleased with catecholamines by exocyt

168 Tissue morphology, abundance of chromogranin A, gut hormones, alpha-defensin, mucin 2, N

169 imulation of secretion in catecholamines and chromogranin A, indicating that secretion of solAPPcyt w

170 cells did not express defensin-5, Muc-2, or chromogranin A, indicating that they were not lineage co

171 The baseline levels of chromogranin A, neuron-specific enolase, and multiple so

172 We also measured fasting serum chromogranin A, neuron-specific enolase, gastrin, glucag

173 Elevated baseline chromogranin A, neuron-specific enolase, placental growt

174 hetic peptides spanning approximately 80% of chromogranin A, one (bovine chromogranin A344-364 [RSMRL

175 gen receptor, prostate specific antigen, and chromogranin A, respectively.

176 secretion also activates the biosynthesis of chromogranin A, the major protein released with catechol

177 lls, we studied the biosynthetic response of chromogranin A, the major soluble protein co-stored and

178 Such coupling triggers the biosynthesis of chromogranin A, the precursor of catestatin.

179 ynthesis of just released catecholamines and chromogranin A, the precursor of the catecholamine relea

180 Here, we probed the role of the chromogranin A-derived peptide pancreastatin (PST: CHGA(

181 Pancreastatin (PST), a chromogranin A-derived peptide, is a potent physiologica

182 orms of gastrin in each, and pyloric mucosal chromogranin A-derived peptides were investigated in the

183 nces in the concentration of pyloric mucosal chromogranin A-derived peptides were recorded between in

184 d secretion in both neuroendocrine cells and chromogranin A-expressing COS7 cells used as a simplifie

185 as predominantly localized to epithelial and chromogranin A-positive endocrine cells.

186 et cell function while negatively regulating chromogranin A-positive enteroendocrine cell number.

187 istochemistry for cytokeratins 7 and 20, and Chromogranin A-proteins which have a well described expr

188 differentiation of thymocytes expressing the chromogranin A-reactive BDC-2.5 and BDC-10.1 TCRs or the

189 The frequencies of islet Ag-reactive chromogranin A-specific CD4(+) T cells and islet specifi

190 al neuroendocrine distribution of endogenous chromogranin A.

191 onserved N- and C-terminal regions of bovine chromogranin A.

192 gation properties as compared with wild-type chromogranin A.

193 0% of cells, and absence of chymotrypsin and chromogranin A.

194 related peptide, neurotensin, serotonin, and chromogranin A.

195 f chymotrypsin, and rare immunoreactivity to chromogranin A.

196 immunostaining for tau-2, synaptophysin, and chromogranin A.

197 n fragments, and was liberated from purified chromogranin A.

198 o label with antibodies specific for APP and chromogranin A.

199 EVSSKDAAE, which is a degradation product of chromogranin A.

200 g, urinary catecholamines/metanephrines, and chromogranin A.

201 ed 2 neuroendocrine tumor markers, ASCL1 and chromogranin A.

202 of cells expressing the pan-endocrine marker chromogranin A.

203 and neuroendocrine markers synaptophysin and chromogranin A.

204 Chromogranins A and B (CGA and CGB) are high capacity, l

205 Chromogranins A and B (CGA and CGB), the major proteins

206 Chromogranins A and B and secretogranin II are a family

207 Chromogranins A and B are high capacity, low affinity ca

208 t express typical LDCV proteins, transfected chromogranins A, B, and brain-derived neurotrophic facto

209 and-Factor[rs12829220] in the control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vit

210 oximately 80% of chromogranin A, one (bovine chromogranin A344-364 [RSMRLSFRARGYGFRGPGLQL], or catest

211 ine release-inhibitory fragment, catestatin (chromogranin A344-364), on agonist-induced desensitizati

212 elated best with synaptophysin compared with chromogranin and CD56/NCAM.

213 of interaction between the heterotetrameric chromogranin and heterotetrameric IP3 receptor but also

214 Size-fractionated chromogranins antagonized nicotinic cholinergic-stimulat

215 Chromogranins are a family of regulated secretory protei

216 Chromogranins are pro-hormone secretory proteins release

217 2+)-dependent aggregation and interaction of chromogranins, as well as several other matrix proteins,

218 olytic fragments of chromogranin A (CgA) and chromogranin B (CgB) represent the major proteins of the

219 at neonatal and adult cardiomyocytes express chromogranin B (CGB), a Ca(2+) binding protein that modu

220 For example, chromogranin B (CGB), a calcium binding protein found in

221 uroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been shown to undergo pH- and

222 tidylinositol-4-phosphate kinase (PIPKI) and chromogranin B (CGB), proteins acting synergistically to

223 the granin proteins chromogranin A (CgA) and chromogranin B (CgB); CgA- and CgB-derived peptides regu

224 Because the isoprostane and Chromogranin B (CHGB) traits shared rho(G), we examined

225 curring genetic variation in the promoter of chromogranin B (CHGB), a major constituent of catecholam

226 om chromogranin A (CHGA), and other CHGA- or chromogranin B (CHGB)-related peptides, in 545 US and 12

227 tory pathway; furthermore, lack of change in chromogranin B and secretogranin II cleavage after dimin

228 Chromogranin B and secretogranin II immunoblots showed n

229 pituitary cell line GH4C1 secretes granins (chromogranin B and secretogranin II) and prolactin by th

230 ce, which enhances accumulation of CD40L and chromogranin B granules at the human TFH cell synapse an

231 phenylethanolamine N-methyl transferase and chromogranin B mRNA was similar in TH-null and wild-type

232 y was confined to heavy fractions containing chromogranin B, a marker of large dense core vesicles.

233 otropin-releasing hormone, secretogranin II, chromogranin B, and pro-SAAS.

234 Chromogranin A, chromogranin B, and secretogranin II, members of the chr

235 provasopressin, prooxytocin, chromogranin A, chromogranin B, and secretogranin II.

236 cells contain dense-core granules marked by chromogranin B, which are normally found in neuronal pre

237 i significantly predicted vascular response: chromogranin B, which encodes a protein that catalyzes c

238 For example, 12 of the 13 chromogranin B-derived peptides found in the present stu

239 Two distinct chromogranin B-derived peptides result from cleavage at

240 Of these 13 chromogranin B-derived peptides, only five contain conse

241 yntaxin, SNAP-25, and N-cadherin, as well as chromogranin B.

242 Golgi network, contained carboxypeptidase E, chromogranin C, and IL-2, and had an electron-dense core

243 HSP70), vesicle- and synapse-related genes (chromogranin C, synaptotagmin IV), neurotransmitter/horm

244 [MiTF], HMB-45, MART-1, CK20, synaptophysin, chromogranin, CD1a, Ki-67) were then employed and the fi

245 boxyl-terminal amidated peptide derived from chromogranin (Cg)A, inhibits secretion of insulin and pa

246 n PC12 cells, these results demonstrate that chromogranins contain independent N- and C-terminal sort

247 techolamine secretory vesicle core proteins (chromogranins) contain an activity that inhibits catecho

248 a chromogranin fragment, which competed with chromogranin for its binding site on the InsP(3)R.

249 ET-1 was both correlated and associated with chromogranin fragment levels, and the 2 were influenced

250 raction between the two proteins by adding a chromogranin fragment, which competed with chromogranin

251 ion; the inhibitor was enriched in processed chromogranin fragments, and was liberated from purified

252 secretory granules of neuroendocrine cells, chromogranins have also been found in the lumen of the e

253 strin levels, mucosal histamine content, and chromogranin immunoreactivity.

254 tures of NE differentiation, as confirmed by chromogranin immunostaining and electron microscopy.

255 elial neoplasia showed NE differentiation by chromogranin immunostaining.

256 sulfide bond is not necessary for sorting of chromogranins in endocrine GH4C1 cells.

257 l disulfide bond is necessary for sorting of chromogranins in neuroendocrine PC12 cells.

258 Hence, in view of the abundance of chromogranins in secretory vesicles and their low pH- an

259 These results show that the InsP(3)R/chromogranin interaction amplifies Ca(2+) release from t

260 mplifies Ca(2+) release from the ER and that chromogranin is an essential component of this intracell

261 fic protein (NESP55), a maternally expressed chromogranin-like protein.

262 markers (MUC1, MUC2, MUC5AC, synaptophysin, chromogranin, neuron specific enolase, epidermal growth

263 f 58, 2%), myogenin (zero of eight, 0%), and chromogranin (one of 46, 2%); and variably reactive for

264 explored the role of these endoproteases in chromogranin processing in AtT-20 mouse pituitary cortic

265 on chromogranin A may be specific within the chromogranin/secretogranin protein family.

266 The chromogranin/secretogranin proteins are costored and cor

267 anin B, and secretogranin II, members of the chromogranin/secretogranin secretory protein family, are

268 tein chromogranin A resulted in an increased chromogranin storage in secretory granules, and stimulat

269 rostate-specific antigen, androgen receptor, chromogranin, synaptophysin, MIB-1, and alpha-methylacyl

270 activated by cytoplasmic InsP(3) and luminal chromogranin, the addition of the fragment reversed the

271 ed aggregation is necessary for sorting of a chromogranin to the regulated secretory pathway of endoc

272 involving kallikrein and Factor XII cleaves chromogranins to active compounds both in vivo and in vi

273 he interaction between the InsP(3) R and the chromogranins, we disrupted the interaction between the